Advanced search
Publication Cover
Libyan Journal of Medicine Volume 5, 2010 - Issue 1
Submit an article Journal homepage
1,790
Views
0
CrossRef citations to date
0
Altmetric
Special Articles

A need for the standardization of the pharmaceutical sector in Libya

Asma Abubakr MustafaDepartment of Pharmaceutics, Faculty of Pharmacy, Al-Arab Medical University, Benghazi, LibyaCorrespondence[email protected]
&
Stefan Robert KowalskiThe School of Pharmacy and Medical Sciences, The University of South Australia, Adelaide, Australia
Article: 5440 | Received 06 Jul 2010, Accepted 22 Sep 2010, Published online: 21 Oct 2010

References

  • Mendis S, Fukino K, Cameron A, Laing R, Filipe A, Khatib O, et al.. The availability and affordability of selected essential medicines for chronic diseases in six low- and middle-income countries. Bull World Health Organ. 2007; 85: 279–88.
  • WHO. How to develop and implement a national drug policy. 2nd ed.Geneva: WHO. 2001. Available from: http://apps.who.int/medicinedocs/pdf/s2283e/s2283e.pdf [cited 4 July 2010].
  • Quick JD, editor. Managing drug supply: the selection, procurement, distribution, and use of pharmaceuticals. 2nd ed.Kumarian Press books on international development. West HartfordCT: Kumarian Press. 1997.
  • Birkett DJ, Mitchell AS, McManus P. A cost-effectiveness approach to drug subsidy and pricing in Australia. Health Aff (Millwood). 2001; 20: 104–14.
  • Cohen J. Global corruption report. Corruption in the pharmaceutical sector. ; 2006. Available from: http://www.transparency.org. [cited 4 July 2010].
  • WHO. Country cooperation strategy for WHO and the Libyan Arab Jamahiriya 2005–2009. Regional Office for the Eastern Mediterranean. , Cairo: WHO. 2006. Available from: http://www.who.int/countryfocus/cooperation_strategy/ccs_lby_en.pdf [cited 4 July 2010].
  • Faitoori A, Mgairbi Z, Alfakri M, Younis J, Hodana B, Bashir A, et al.. A study of the Libyan medicines situation. Libyan Central Bank. Libya, 2003
  • Ekhshaibah E. Channels of medical supply in Libya. In:The fifth national pharmaceutical sciences conference; April22–24; 2005. Benghazi, Libya, 1–69.
  • Cohen J. Improving transparency in pharmaceutical systems: strengthening critical decision points against corruption. Latin American and Caribbean Region, human development network. ; 2002. Available from: http://www.u4.no/pdf/?file = /themes/health/cohen_wb_paper_pharma2002.pdf [cited 4 July 2010].
  • Gautam CS, Aditya S. Irrational drug combinations: need to sensitize undergraduates. Indian J Pharmacol. 2006; 38: 169–70.
  • Poudel A, Palaian S, Shankar PR, Jayasekera J, Izham MIM. Irrational fixed dose combinations in Nepal: need for intervention. Kathmandu Univ Med J. 2008; 6: 399–405.
  • Newton PN, Green M, Fernández F, Day N, White N. Counterfeit anti-infective drugs. Lancet Infect Dis. 2006; 6: 602–13.
  • Caudron JM, Ford N, Henkens M, Mace C, Kiddle-Monroe R, Pinel J. Substandard medicines in resource-poor settings: a problem that can no longer be ignored. Trop Med Int Health. 2008; 13: 1062–72.
  • Newton PN, Green MD, Fernández FM. Impact of poor-quality medicines in the developing world. Trends Pharmacol Sci. 2010; 31: 99–101.
  • WHO. The world medicines situation. Geneva: WHO. 2004. Available from: http://apps.who.int/medicinedocs/en/d/Js6160e/ [cited 4 July 2010].
  • Ravinetto RM, Cloëz S, Scouflaire-Mallet SM, Vandenbergh D. Poor-quality medicines in developing countries. Lancet Infect Dis. 2009; 9: 267–68.
  • WHO. The selection of essential medicines. WHO policy perspectives on medicines. Geneva: WHO. 2002. Available from: http://whqlibdoc.who.int/hq/2002/WHO_EDM_2002.2.pdf [cited 4 July 2010].
  • Hogerzeil HV. The concept of essential medicines: lessons for rich countries. BMJ. 2004; 329: 1169–72.
  • Laing R, Waning B, Gray A, Ford N, Hoen E. 25 years of the WHO essential medicines lists: progress and challenges. Lancet. 2003; 361: 1723–29.
  • Laing RO, Hogerzeil HV, Ross-Degnan D. Ten recommendations to improve use of medicines in developing countries. Health Policy Plan. 2001; 16: 13–20.
  • WHO. Promoting rational use of medicines: core components. WHO policy perspectives on medicines No. 5. Geneva: WHO. 2002. Available from: http://apps.who.int/medicinedocs/pdf/h3011e/h3011e.pdf [cited 4 July 2010].
  • Ellner A, Dillner L, Nash B, Godlee F. Essential medicines in the United States. BMJ Publishing Group. 2003. Available from: http://www.unitedhealthfoundation.org/Essential%20medicines%20-%20final.pdf [cited 4 July 2010].
  • Okonjo-Iweala N, Osafo-Kwaako P. Improving health statistics in Africa. Lancet. 2007; 370: 1527–8.
  • Reidenberg MM. World Health Organization program for the selection and use of essential medicines. Clin Pharmacol Ther. 2007; 81: 603–6.
  • Le Grand A, Hogerzeil HV, Haaijer-Ruskamp F. Review article. Intervention research in rational use of drugs: a review. Health Policy Plan. 1999; 14: 89–102.
  • WHO. The role of education in the rational use of medicines. Regional Office for South-East Asia. ; 2006. Available from: http://www.searo.who.int/LinkFiles/Reports_vision.pdf [cited 4 July 2010].
  • Bakoush O, Al-Tubuly A, Ashammakhi N, Elkhammas E. PubMed medical publications from Libya. Libyan J Med. 2007; 2: 125–8.
  • Naja SA, Idris M, Khan A. Drugs cost more at primary health clinics: an experience from Libya. Health Policy Plan. 1988; 3: 69–73.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.